Monitoring of dabigatran anticoagulation and its reversal in vitro by thrombelastography.
(2014) In International Journal of Cardiology 176(3). p.794-799- Abstract
- Dabigatran etexilate, a pro-drug of a direct thrombin inhibitor, was approved a few years ago for non-valvular atrial fibrillation and deep venous thrombosis. Rapid monitoring of the dabigatran level is essential in trauma and bleeding patients but the traditional plasma-based assays may not sufficiently display the effect. Furthermore, no antidote exists and reversal of the anticoagulant effect is impossible or difficult. The present study investigated the in vitro effect of dabigatran on whole blood thromboelastography (TEG) and its reversal by recombinant activated factor VII and prothrombin complex concentrate.
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/4613886
- author
- Solbeck, Sacha ; Meyer, Martin A S ; Johansson, Pär I ; Meyer, Anna Sina P ; Cotton, Bryan A ; Stensballe, Jakob ; Schött, Ulf LU and Ostrowski, Sisse R
- organization
- publishing date
- 2014
- type
- Contribution to journal
- publication status
- published
- subject
- in
- International Journal of Cardiology
- volume
- 176
- issue
- 3
- pages
- 794 - 799
- publisher
- Elsevier
- external identifiers
-
- pmid:25156858
- wos:000343893300059
- pmid:25156858
- scopus:84908214306
- ISSN
- 0167-5273
- DOI
- 10.1016/j.ijcard.2014.07.084
- project
- Koagulation vid kirurgi och kritisk sjukdom
- language
- English
- LU publication?
- yes
- id
- 8e0e62ca-d3b8-4159-bc19-37a87c3a7418 (old id 4613886)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/25156858?dopt=Abstract
- date added to LUP
- 2016-04-01 10:33:06
- date last changed
- 2022-02-10 03:18:42
@article{8e0e62ca-d3b8-4159-bc19-37a87c3a7418, abstract = {{Dabigatran etexilate, a pro-drug of a direct thrombin inhibitor, was approved a few years ago for non-valvular atrial fibrillation and deep venous thrombosis. Rapid monitoring of the dabigatran level is essential in trauma and bleeding patients but the traditional plasma-based assays may not sufficiently display the effect. Furthermore, no antidote exists and reversal of the anticoagulant effect is impossible or difficult. The present study investigated the in vitro effect of dabigatran on whole blood thromboelastography (TEG) and its reversal by recombinant activated factor VII and prothrombin complex concentrate.}}, author = {{Solbeck, Sacha and Meyer, Martin A S and Johansson, Pär I and Meyer, Anna Sina P and Cotton, Bryan A and Stensballe, Jakob and Schött, Ulf and Ostrowski, Sisse R}}, issn = {{0167-5273}}, language = {{eng}}, number = {{3}}, pages = {{794--799}}, publisher = {{Elsevier}}, series = {{International Journal of Cardiology}}, title = {{Monitoring of dabigatran anticoagulation and its reversal in vitro by thrombelastography.}}, url = {{https://lup.lub.lu.se/search/files/15812578/1936263.pdf}}, doi = {{10.1016/j.ijcard.2014.07.084}}, volume = {{176}}, year = {{2014}}, }